Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma

LESSONS LEARNED: Despite the initial optimism for using immune checkpoint inhibition in the treatment of multiple myeloma, subsequent clinical studies have been disappointing. Preclinical studies have suggested that priming the immune system with various modalities in addition to checkpoint inhibiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazandjian, Dickran, Dew, Alexander, Hill, Elizabeth, Ramirez, Elizabeth Gil, Morrison, Candis, Mena, Esther, Lindenberg, Liza, Yuan, Constance, Maric, Irina, Wang, Hao‐Wei, Calvo, Katherine, Dulau‐Florea, Alina, Roswarski, Joseph, Emanuel, Michael, Braylan, Raul, Turkbey, Baris, Choyke, Peter, Camphausen, Kevin, Stetler‐Stevenson, Maryalice, Steinberg, Seth M., Figg, William D., C. Jones, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018315/
https://www.ncbi.nlm.nih.gov/pubmed/33554406
http://dx.doi.org/10.1002/onco.13712

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018315/
https://www.ncbi.nlm.nih.gov/pubmed/33554406
http://dx.doi.org/10.1002/onco.13712

Ejemplares similares